John Williams, Ph.D. (IMAGE)
Caption
Researchers from City of Hope have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. "The bottom line is that tumors adapt to CAR T therapies, leading to treatment failure and cancer relapse. To remain effective, our therapies need to adapt, too,” said co-senior author John Williams, Ph.D., director of City of Hope’s X-ray Crystallography Core. “City of Hope has created a system that allows us to reconfigure these potent cancer killers as the tumor progresses."
Credit
City of Hope
Usage Restrictions
Use credit info
License
Original content